Progress in brain targeting drug delivery system by nasal route

Khan, Abdur Rauf; Liu, Mengrui; Khan, Muhammad Wasim; Zhai, Guangxi

doi:10.1016/j.jconrel.2017.09.001

Cited by 304 publications

(207 citation statements)

References 260 publications

Supporting

Mentioning

177

Contrasting

Order By: Relevance

“…The nasal mucosa allows direct delivery of drugs to the brain bypassing the blood brain barrier (BBB). It avoids hepatic clearance and drug degradation by liver enzymes, and therefore, increases the effect of neurotherapy [3].…”

Section: Introductionmentioning

confidence: 99%

Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model

Pashirova

Zueva

Петров

et al. 2018

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model

Pashirova

Zueva

Петров

et al. 2018

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

“…CAs or therapeutic drugs can be delivered from the olfactory mucosa to the brain by neuronal cells through the olfactory pathway, which consists of olfactory epithelium in nasal cavity, lamina propria, and olfactory bulb in the CNS (Khan et al, 2017). Since the nasal passage is the only direct connection between the external environment and the brain, it provides an applicable method for CAs or therapeutic drugs to enter the brain by bypassing the BBB rather than to cross it (Salama et al, 2017).…”

Section: The Carriermentioning

confidence: 99%

“…Since the nasal passage is the only direct connection between the external environment and the brain, it provides an applicable method for CAs or therapeutic drugs to enter the brain by bypassing the BBB rather than to cross it (Salama et al, 2017). Thus, the olfactory pathway is more efficient for reducing hepatic/renal clearance and the systemic exposure (Akilo et al, 2016;Khan et al, 2017).…”

Section: The Carriermentioning

confidence: 99%

Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease

Luo

Zhu

et al. 2020

Front. Cell. Neurosci.

View full text Add to dashboard Cite

“…Together with the drug targeting ability nanoparticle also promote the drug permeation through nasal mucosa, increases the brain bioavailability of the drug, protects the drug enzymatic degradation and increases the drug retention time in the nasal cavity (chitosan nanoparticle). 73,74 Kuo et al (2019) targeted the carmustine, etoposide and doxorubicin to the glioblastoma cells of the human brain by encapsulating the drug into folic acid and wheat germ agglutinin conjugated methoxy PEG-PCL nanoparticle. The wheat germ agglutinin and folic acid assist the targeting efficiency of the system while mPEG and PCL control the drug release behavior.…”

Section: Polymeric Nanoparticlementioning

confidence: 99%

<p>Recent expansions of novel strategies towards the drug targeting into the brain</p>

Alexander¹,

Agrawal²,

Uddin³

et al. 2019

IJN

122

View full text Add to dashboard Cite

The treatment of central nervous system (CNS) disorders always remains a challenge for the researchers. The presence of various physiological barriers, primarily the blood–brain barrier (BBB) limits the accessibility of the brain and hinders the efficacy of various drug therapies. Hence, drug targeting to the brain, particularly to the diseased cells by circumventing the physiological barriers is essential to develop a promising therapy for the treatment of brain disorders. Presently, the investigations emphasize the role of different nanocarrier systems or surface modified target specific novel carrier system to improve the efficiency and reduce the side effects of the brain therapeutics. Such approaches supposed to circumvent the BBB or have the ability to cross the barrier function and thus increases the drug concentration in the brain. Although the efficacy of novel carrier system depends upon various physiological factors like active efflux transport, protein corona of the brain, stability, and toxicity of the nanocarrier, physicochemical properties, patient-related factors and many more. Hence, to develop a promising carrier system, it is essential to understand the physiology of the brain and BBB and also the other associated factors. Along with this, some alternative route like direct nose-to-brain drug delivery can also offer a better means to access the brain without exposure of the BBB. In this review, we have discussed the role of various physiological barriers including the BBB and blood-cerebrospinal fluid barrier (BCSFB) on the drug therapy and the mechanism of drug transport across the BBB. Further, we discussed different novel strategies for brain targeting of drug including, polymeric nanoparticles, lipidic nanoparticles, inorganic nanoparticles, liposomes, nanogels, nanoemulsions, dendrimers, quantum dots, etc. along with the intranasal drug delivery to the brain. We have also illustrated various factors affecting the drug targeting efficiency of the developed novel carrier system.

show abstract

Progress in brain targeting drug delivery system by nasal route

Cited by 304 publications

References 260 publications

Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model

Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model

Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease

<p>Recent expansions of novel strategies towards the drug targeting into the brain</p>

Contact Info

Product

Resources

About